维持性血液透析与腹膜透析患者的处方模式及药物费用
该研究基于加拿大阿尔伯塔省2019年3月31日的2248例维持性透析成人(HD 1781例,PD 467例),分析多重用药的患病率与费用。中位药物类别数为6,每日药片负担中位8.0片,12%被处方至少一种肾衰竭禁忌药物;透析患者药片负担和费用分别较匹配的普通人群高3倍和10倍以上。
要点
- 透析患者中位使用6类处方药,每日药片负担中位8.0片。
- 12%的透析患者被处方至少一种肾衰竭禁忌药物。
- 透析患者药片负担和年人均费用分别较匹配普通人群高3倍和10倍以上。
核心结论
- 透析患者处方药物使用和相关费用显著高于普通人群,需要有效的减处方方法。
研究设计与样本
- 基于人群的队列研究,纳入加拿大阿尔伯塔省2019年3月31日≥20岁维持性HD或PD成人共2248例(HD 1781例,PD 467例),并与年龄性别匹配的普通人群比较。
主要发现
- 中位处方药物类别数为6(IQR 4-8),中位每日药片负担为8.0片(IQR 4.6-12.6)。
- 5%的患者每日处方药片数≥21.7片,16.5%的患者每日处方药片数≥15片。
- 12%的患者被处方至少一种在肾衰竭中禁忌的药物。
- 在1063例≥65岁患者中,中位潜在不适当药物(PIM)类别数为2(IQR 1-2),中位PIM药片负担为1.2片/天(IQR 0.5-2.4)。
临床怎么用
- 透析患者应常规评估多重用药和肾衰竭禁忌药物,关注高药片负担及费用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Polypharmacy is a significant clinical issue for patients on dialysis but has been incompletely studied. We investigated the prevalence and costs of polypharmacy in a population-based cohort of participants treated with haemodialysis (HD) or peritoneal dialysis (PD). METHODS: We studied adults ≥20 years of age in Alberta, Canada receiving maintenance HD or PD as of 31 March 2019. We characterized participants as users of 0-29 drug categories of interest and those ≥65 years of age as users/non-users of potentially inappropriate medications (PIMs). We calculated the number of drug categories, daily pill burden, total annual cost and annual cost per participant and compared this to an age- and sex-matched cohort from the general Alberta population. RESULTS: Among 2248 participants (mean age 63 years; 39% female) on HD (n = 1781) or PD (n = 467), the median number of prescribed drug categories was 6 [interquartile range (IQR) 4-8] and the median daily pill burden was 8.0 (IQR 4.6-12.6), with 5% prescribed ≥21.7 pills/day and 16.5% prescribed ≥15 pills/day. Twelve percent were prescribed at least one drug that is contraindicated in kidney failure. The median annual per-participant cost was ${\$}$3831, totalling ≈${\$}$11.6 million annually for all participants. When restricting to the 1063 participants ≥65 years of age, the median number of PIM categories was 2 (IQR 1-2), with a median PIM pill burden of 1.2 pills/day (IQR 0.5-2.4). Compared with PD participants, HD participants had a similar daily pill burden, higher use of PIMs and higher annual per-participant cost. Pill burden and associated costs for participants on dialysis were >3-fold and 10-fold higher, respectively, compared with the matched participants from the general population. CONCLUSION: Participants on dialysis have markedly higher use of prescription medications and associated costs than the general population. Effective methods to de-prescribe in the dialysis population are needed.
引用
- Ghimire A, Lloyd AM, Bello AK, et al. Prescribing patterns and medication costs in patients on maintenance haemodialysis and peritoneal dialysis. Nephrol Dial Transplant. 2025. PMID: 38964833. doi:10.1093/ndt/gfae154
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。